February 5, 2026 — Bishkek, Kyrgyzstan
Delta Medical Kyrgyzstan took part in the scientific-practical conference “Hepatitis B/D: Modern Challenges, Diagnostics, and the Experience of International Cooperation,” held in the Kyrgyz capital. The meeting convened regulators, clinicians, international organizations, patient advocates, and pharmaceutical industry representatives to examine the current state of hepatitis B and D management in the Kyrgyz Republic and identify actionable next steps.
Why This Conference Matters
Kyrgyzstan has historically been classified among countries with high endemicity for viral hepatitis, though recent seroprevalence data suggest the burden of hepatitis B may be shifting toward intermediate levels. Despite progress in childhood vaccination (the country received WHO validation of hepatitis B control targets in 2023), significant gaps remain in the diagnosis and treatment of chronic hepatitis B among adults. Late presentation, limited access to optimal antiviral therapies, and fragmented coordination between healthcare institutions and patient communities continue to challenge the national response.
The conference was designed to confront these realities head-on, bringing together stakeholders who rarely share the same room.
A Multistakeholder Format
The meeting assembled a notably broad range of participants:
- Ministry of Health of the Kyrgyz Republic
- Kyrgyzpharmacia, the state pharmaceutical enterprise established in 2023 under the Ministry of Health to centralize procurement and improve access to affordable medicines across the public health system
- UNDP and other international organizations active in the region
- Stop Hepatitis, a Kyrgyz patient advocacy community that has emerged as a leading voice for people living with chronic viral hepatitis in the country
- Practicing hepatologists from across the republic
- Pharmaceutical industry representatives, including Delta Medical Kyrgyzstan
This broad format enabled a level of candor that is rare in formal settings.
The Treatment Landscape Under Scrutiny
A central topic of discussion was the current standard of care for chronic hepatitis B within the Kyrgyz public health system. Patients receiving state-funded treatment currently have access primarily to generic entecavir. Representatives of the Stop Hepatitis patient community used the conference as a platform to raise concerns they had gathered directly from patients, including reports of tolerability issues and disease recurrence.
The discussion also addressed the positioning of tenofovir alafenamide (Vemlidy®, manufactured by Gilead Sciences) within the evolving therapeutic landscape. Vemlidy, a targeted prodrug of tenofovir approved for the treatment of chronic HBV infection in adults with compensated liver disease, has demonstrated antiviral efficacy with a favorable renal and bone safety profile in international Phase 3 clinical trials. Conference participants examined how newer antiviral options could fit within the Kyrgyz national treatment framework, given the country’s resource constraints and procurement realities.
Delta Medical’s Role on the Ground
For Delta Medical Kyrgyzstan, participation in this conference extended beyond the formal program. Following the session, the company’s medical representative Aysuluu Samudinova engaged directly with the leadership of Stop Hepatitis, practicing hepatologists, and patients to better understand unmet needs and information gaps in the current care pathway.
These conversations reinforced the importance of ensuring that clinicians and patients have access to balanced, evidence-based information about available treatment options, a role Delta Medical is well positioned to support as a distributor with established relationships across the Kyrgyz healthcare system.
Agreed Next Steps
A concrete outcome of the meeting was an agreement between Delta Medical Kyrgyzstan and the Stop Hepatitis patient community to hold a dedicated follow-up session. The objective: to develop a coordinated advocacy strategy for working with government institutions and health authorities to improve the standard of care for patients with chronic hepatitis B in the Kyrgyz Republic.
A Consistent Approach
Delta Medical Kyrgyzstan’s presence at this conference reflects a broader pattern. Across the markets it serves, Delta Medical works to connect physicians, patients, and health systems by facilitating access to clinical evidence, supporting professional dialogue, and engaging constructively with the regulatory and institutional frameworks that shape how patients receive care.
About Delta Medical
Delta Medical is a pharmaceutical and medical device marketing and distribution company operating across Ukraine, CIS, and EAEU territories. Through partnerships with leading international manufacturers, the company works to improve patient outcomes by supporting healthcare professionals with access to innovative therapies and continuing medical education.
